메뉴 건너뛰기




Volumn 17, Issue 4, 2010, Pages 214-223

New drugs for pediatric epilepsy

Author keywords

[No Author keywords available]

Indexed keywords

BRIVARACETAM; CARBAMAZEPINE; CLOBAZAM; CYTOCHROME P450; HARKOSERIDE; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PLACEBO; PRIMIDONE; RETIGABINE; RUFINAMIDE; VALPROIC ACID; VIGABATRIN;

EID: 78650275995     PISSN: 10719091     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.spen.2010.10.003     Document Type: Review
Times cited : (33)

References (105)
  • 1
    • 33644800598 scopus 로고    scopus 로고
    • Prevalence of childhood epilepsy and distribution of epileptic syndromes: A population-based survey in Okayama, Japan
    • Oka E., Ohtsuka Y., Yoshinaga H., et al. Prevalence of childhood epilepsy and distribution of epileptic syndromes: A population-based survey in Okayama, Japan. Epilepsia 2006, 47:626-630.
    • (2006) Epilepsia , vol.47 , pp. 626-630
    • Oka, E.1    Ohtsuka, Y.2    Yoshinaga, H.3
  • 2
    • 0025954532 scopus 로고
    • Prevalence of epilepsy in Rochester, Minnesota: 1940-80
    • Hauser W.A., Annegers J.F., Kurland L.T. Prevalence of epilepsy in Rochester, Minnesota: 1940-80. Epilepsia 1991, 32:429-445.
    • (1991) Epilepsia , vol.32 , pp. 429-445
    • Hauser, W.A.1    Annegers, J.F.2    Kurland, L.T.3
  • 3
    • 0029051911 scopus 로고
    • Prevalence of epilepsy and epileptic seizures in 10 year old children: Results from the Metropolitan Atlanta Developmental Disabilities Study
    • Murphy C.C., Trevathan E., Yeargin-Allsopp M. Prevalence of epilepsy and epileptic seizures in 10 year old children: Results from the Metropolitan Atlanta Developmental Disabilities Study. Epilepsia 1995, 36:866-872.
    • (1995) Epilepsia , vol.36 , pp. 866-872
    • Murphy, C.C.1    Trevathan, E.2    Yeargin-Allsopp, M.3
  • 4
    • 0033863879 scopus 로고    scopus 로고
    • Predictors of multiple seizures in a cohort of children prospectively followed from the time of their first unprovoked seizure
    • Shinnar S., Berg A.T., O'Dell C., et al. Predictors of multiple seizures in a cohort of children prospectively followed from the time of their first unprovoked seizure. Ann Neurol 2000, 48:140-147.
    • (2000) Ann Neurol , vol.48 , pp. 140-147
    • Shinnar, S.1    Berg, A.T.2    O'Dell, C.3
  • 5
    • 0033821439 scopus 로고    scopus 로고
    • Epilepsy can be diagnosed when the first two seizures occur on the same day
    • Camfield P., Camfield C. Epilepsy can be diagnosed when the first two seizures occur on the same day. Epilepsia 2000, 41:1230-1233.
    • (2000) Epilepsia , vol.41 , pp. 1230-1233
    • Camfield, P.1    Camfield, C.2
  • 6
    • 37749044216 scopus 로고    scopus 로고
    • Special considerations for a first seizure in childhood and adolescence
    • Camfield P., Camfield C. Special considerations for a first seizure in childhood and adolescence. Epilepsia 2008, 49(suppl 1):40-44.
    • (2008) Epilepsia , vol.49 , Issue.SUPPL. 1 , pp. 40-44
    • Camfield, P.1    Camfield, C.2
  • 7
    • 60749087127 scopus 로고    scopus 로고
    • When to start drug treatment for childhood epilepsy: The clinical-epidemiological evidence
    • Arts W.F., Geerts A.T. When to start drug treatment for childhood epilepsy: The clinical-epidemiological evidence. Eur J Paediatr Neurol 2009, 13:93-101.
    • (2009) Eur J Paediatr Neurol , vol.13 , pp. 93-101
    • Arts, W.F.1    Geerts, A.T.2
  • 8
    • 0041386052 scopus 로고    scopus 로고
    • Vagus-nerve stimulation for the treatment of epilepsy
    • Ben-Menachem E. Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol 2002, 1:477-482.
    • (2002) Lancet Neurol , vol.1 , pp. 477-482
    • Ben-Menachem, E.1
  • 9
    • 77953203585 scopus 로고    scopus 로고
    • Pediatric epilepsy surgery: looking back while moving forward
    • Donner E.J., Goodkin H.P. Pediatric epilepsy surgery: looking back while moving forward. Neurology 2010, 74:1756-1757.
    • (2010) Neurology , vol.74 , pp. 1756-1757
    • Donner, E.J.1    Goodkin, H.P.2
  • 10
    • 58149176094 scopus 로고    scopus 로고
    • First-drug treatment failures in children newly diagnosed with epilepsy
    • Dudley R.W., Penney S.J., Buckley D.J. First-drug treatment failures in children newly diagnosed with epilepsy. Pediatr Neurol 2009, 40:71-77.
    • (2009) Pediatr Neurol , vol.40 , pp. 71-77
    • Dudley, R.W.1    Penney, S.J.2    Buckley, D.J.3
  • 11
    • 34248589701 scopus 로고    scopus 로고
    • Prioritizing children's medicines for research: A pharmaco-epidemiological study of antiepileptic drugs
    • Ackers R., Murray M.L., Besag F.M., et al. Prioritizing children's medicines for research: A pharmaco-epidemiological study of antiepileptic drugs. Br J Clin Pharmacol 2007, 63:689-697.
    • (2007) Br J Clin Pharmacol , vol.63 , pp. 689-697
    • Ackers, R.1    Murray, M.L.2    Besag, F.M.3
  • 13
    • 70449730891 scopus 로고    scopus 로고
    • Lacosamide: an adjunctive agent for partial-onset seizures and potential therapy for neuropathic pain
    • Harris J.A., Murphy J.A. Lacosamide: an adjunctive agent for partial-onset seizures and potential therapy for neuropathic pain. Ann Pharmacother 2009, 43:1809-1817.
    • (2009) Ann Pharmacother , vol.43 , pp. 1809-1817
    • Harris, J.A.1    Murphy, J.A.2
  • 14
    • 37349071555 scopus 로고    scopus 로고
    • The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels
    • Errington A.C., Stöhr T., Heers C., et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008, 73:157-169.
    • (2008) Mol Pharmacol , vol.73 , pp. 157-169
    • Errington, A.C.1    Stöhr, T.2    Heers, C.3
  • 15
    • 34247855780 scopus 로고    scopus 로고
    • Lacosamide: a review of preclinical properties
    • Beyreuther B.K., Freitag J., Heers C., et al. Lacosamide: a review of preclinical properties. CNS Drug Res 2007, 13:21-42.
    • (2007) CNS Drug Res , vol.13 , pp. 21-42
    • Beyreuther, B.K.1    Freitag, J.2    Heers, C.3
  • 16
    • 67649388104 scopus 로고    scopus 로고
    • Lacosamide: A new approach to target voltage-gated sodium currents in epileptic disorders
    • Curia G., Biagini G., Perucca E., et al. Lacosamide: A new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs 2009, 23:555-568.
    • (2009) CNS Drugs , vol.23 , pp. 555-568
    • Curia, G.1    Biagini, G.2    Perucca, E.3
  • 17
    • 34447344551 scopus 로고    scopus 로고
    • Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures
    • Ben-Menachem E., Biton V., Jatuzis D., et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007, 48:1308-1317.
    • (2007) Epilepsia , vol.48 , pp. 1308-1317
    • Ben-Menachem, E.1    Biton, V.2    Jatuzis, D.3
  • 18
    • 33846194013 scopus 로고    scopus 로고
    • Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (Eilat. VIII)
    • Bialer M., Johannessen S.I., Kupferberg H.J., et al. Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (Eilat. VIII). Epilepsy Res 2007, 73:1-52.
    • (2007) Epilepsy Res , vol.73 , pp. 1-52
    • Bialer, M.1    Johannessen, S.I.2    Kupferberg, H.J.3
  • 19
    • 61849088333 scopus 로고    scopus 로고
    • Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial
    • Halasz P., Kälviäinen R., Mazurkiewicz-Beldzińska M., et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009, 50:443-453.
    • (2009) Epilepsia , vol.50 , pp. 443-453
    • Halasz, P.1    Kälviäinen, R.2    Mazurkiewicz-Beldzińska, M.3
  • 20
    • 77953033494 scopus 로고    scopus 로고
    • Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial
    • Chung S., Sperling M.R., Biton V., et al. Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial. Epilepsia 2010, 51:958-967.
    • (2010) Epilepsia , vol.51 , pp. 958-967
    • Chung, S.1    Sperling, M.R.2    Biton, V.3
  • 21
    • 70449533094 scopus 로고    scopus 로고
    • Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany
    • Wehner T., Bauer S., Hamer H.M., et al. Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009, 16:423-425.
    • (2009) Epilepsy Behav , vol.16 , pp. 423-425
    • Wehner, T.1    Bauer, S.2    Hamer, H.M.3
  • 22
    • 17444446765 scopus 로고    scopus 로고
    • Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties
    • Kehne J.H., Kane M., Chaney S.F., et al. Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties. Epilepsy Res 1997, 27:41-54.
    • (1997) Epilepsy Res , vol.27 , pp. 41-54
    • Kehne, J.H.1    Kane, M.2    Chaney, S.F.3
  • 23
    • 59749093137 scopus 로고    scopus 로고
    • Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy
    • Kellinghaus C., Berning S., Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav 2009, 14:429-431.
    • (2009) Epilepsy Behav , vol.14 , pp. 429-431
    • Kellinghaus, C.1    Berning, S.2    Besselmann, M.3
  • 24
    • 75649100509 scopus 로고    scopus 로고
    • Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide
    • Tilz C., Resch R., Hofer T., et al. Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide. Epilepsia 2010, 51:316-317.
    • (2010) Epilepsia , vol.51 , pp. 316-317
    • Tilz, C.1    Resch, R.2    Hofer, T.3
  • 25
    • 39749167069 scopus 로고    scopus 로고
    • Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures
    • Biton V., Rosenfeld W.E., Whitesides J., et al. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008, 49:418-424.
    • (2008) Epilepsia , vol.49 , pp. 418-424
    • Biton, V.1    Rosenfeld, W.E.2    Whitesides, J.3
  • 26
    • 4043070529 scopus 로고    scopus 로고
    • Diagnosis of infantile spasms, Lennox-Gastaut syndrome, and progressive myoclonic epilepsy
    • Shields W.D. Diagnosis of infantile spasms, Lennox-Gastaut syndrome, and progressive myoclonic epilepsy. Epilepsia 2004, 45(suppl 5):2-4.
    • (2004) Epilepsia , vol.45 , Issue.SUPPL. 5 , pp. 2-4
    • Shields, W.D.1
  • 27
    • 85129694326 scopus 로고    scopus 로고
    • Rufinamide: A novel broad-spectrum antiepileptic drug
    • Wheless J.W., Vazquez B. Rufinamide: A novel broad-spectrum antiepileptic drug. Epilepsy Curr 2010, 10:1-6.
    • (2010) Epilepsy Curr , vol.10 , pp. 1-6
    • Wheless, J.W.1    Vazquez, B.2
  • 29
    • 47249119666 scopus 로고    scopus 로고
    • The anticonvulsant profile of Rufinamide (CGP 33101) in rodent seizure models
    • White H.S., Franklin M.R., Kupferberg H.J., et al. The anticonvulsant profile of Rufinamide (CGP 33101) in rodent seizure models. Epilepsia 2008, 49:1213-1220.
    • (2008) Epilepsia , vol.49 , pp. 1213-1220
    • White, H.S.1    Franklin, M.R.2    Kupferberg, H.J.3
  • 30
    • 68149096743 scopus 로고    scopus 로고
    • Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: A randomized placebo-controlled trial
    • Brodie M.J., Rosenfeld W.E., Vazquez B., et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: A randomized placebo-controlled trial. Epilepsia 2009, 50:1899-1909.
    • (2009) Epilepsia , vol.50 , pp. 1899-1909
    • Brodie, M.J.1    Rosenfeld, W.E.2    Vazquez, B.3
  • 31
    • 76049084221 scopus 로고    scopus 로고
    • A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of Rufinamide in adults and adolescents with inadequately controlled partial seizures
    • Elger C.E., Stefan H., Mann A., et al. A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of Rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res 2010, 88:255-263.
    • (2010) Epilepsy Res , vol.88 , pp. 255-263
    • Elger, C.E.1    Stefan, H.2    Mann, A.3
  • 32
    • 77952240784 scopus 로고    scopus 로고
    • First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy
    • Kluger G., Haberlandt E., Kurlemann G., et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav 2010, 17:546-548.
    • (2010) Epilepsy Behav , vol.17 , pp. 546-548
    • Kluger, G.1    Haberlandt, E.2    Kurlemann, G.3
  • 33
    • 44949184519 scopus 로고    scopus 로고
    • Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome
    • Glauser T., Kluger G., Sachdeo R., et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008, 70:1950-1958.
    • (2008) Neurology , vol.70 , pp. 1950-1958
    • Glauser, T.1    Kluger, G.2    Sachdeo, R.3
  • 34
    • 75149122341 scopus 로고    scopus 로고
    • Safety and tolerability of rufinamide in children with epilepsy: A pooled analysis of 7 clinical studies
    • Wheless J.W., Conry J., Krauss G., et al. Safety and tolerability of rufinamide in children with epilepsy: A pooled analysis of 7 clinical studies. J Child Neurol 2009, 24:1520-1525.
    • (2009) J Child Neurol , vol.24 , pp. 1520-1525
    • Wheless, J.W.1    Conry, J.2    Krauss, G.3
  • 35
    • 33746111455 scopus 로고    scopus 로고
    • The effect of the new antiepileptic drug rufinamide on cognitive functions
    • Aldenkamp A.P., Alpherts W.C. The effect of the new antiepileptic drug rufinamide on cognitive functions. Epilepsia 2006, 47:1153-1159.
    • (2006) Epilepsia , vol.47 , pp. 1153-1159
    • Aldenkamp, A.P.1    Alpherts, W.C.2
  • 36
    • 51449119865 scopus 로고    scopus 로고
    • Pharmacological management of epilepsy: Recent advances and future prospects
    • Johannessen Landmark C., Johannessen S.I. Pharmacological management of epilepsy: Recent advances and future prospects. Drugs 2008, 68:1925-1939.
    • (2008) Drugs , vol.68 , pp. 1925-1939
    • Johannessen Landmark, C.1    Johannessen, S.I.2
  • 37
    • 77949266502 scopus 로고    scopus 로고
    • Supporting the recommended paediatric dosing regimen for rufinamide in Lennox-Gastaut syndrome using clinical trial simulation
    • Marchand M., Fuseau E., Critchley D.J. Supporting the recommended paediatric dosing regimen for rufinamide in Lennox-Gastaut syndrome using clinical trial simulation. J Pharmacokinet Pharmacodyn 2010, 37:99-118.
    • (2010) J Pharmacokinet Pharmacodyn , vol.37 , pp. 99-118
    • Marchand, M.1    Fuseau, E.2    Critchley, D.J.3
  • 39
    • 0032977994 scopus 로고    scopus 로고
    • Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures
    • Petroff O.A., Hyder F., Collins T., et al. Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures. Epilepsia 1999, 40:958-964.
    • (1999) Epilepsia , vol.40 , pp. 958-964
    • Petroff, O.A.1    Hyder, F.2    Collins, T.3
  • 40
    • 0035940574 scopus 로고    scopus 로고
    • Randomized trial of vigabatrin in patients with infantile spasms
    • Elterman R.D., Shields W.D., Mansfield K.A., et al. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001, 57:1416-1421.
    • (2001) Neurology , vol.57 , pp. 1416-1421
    • Elterman, R.D.1    Shields, W.D.2    Mansfield, K.A.3
  • 41
    • 47249112141 scopus 로고    scopus 로고
    • Vigabatrin in the treatment of childhood epilepsy: A retrospective chart review of efficacy and safety profile
    • Camposano S.E., Major P., Halpern E., et al. Vigabatrin in the treatment of childhood epilepsy: A retrospective chart review of efficacy and safety profile. Epilepsia 2008, 49:1186-1191.
    • (2008) Epilepsia , vol.49 , pp. 1186-1191
    • Camposano, S.E.1    Major, P.2    Halpern, E.3
  • 43
    • 26844507605 scopus 로고    scopus 로고
    • The United Kingdom infantile spasms Study (UKISS): Comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: A multicentre randomised trial
    • Lux A.L., Edwards S.W., Hancock E., et al. The United Kingdom infantile spasms Study (UKISS): Comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: A multicentre randomised trial. Lancet Neurol 2005, 4:712-717.
    • (2005) Lancet Neurol , vol.4 , pp. 712-717
    • Lux, A.L.1    Edwards, S.W.2    Hancock, E.3
  • 44
    • 8444249008 scopus 로고    scopus 로고
    • The United Kingdom Infantile Spasms Study: Comparing vigabatrin with prednisolone or tetracosactide at 14 days: A multicentre, randomised controlled trial
    • Lux A.L., Edwards S.W., Hancock E., et al. The United Kingdom Infantile Spasms Study: Comparing vigabatrin with prednisolone or tetracosactide at 14 days: A multicentre, randomised controlled trial. Lancet 2004, 364:1773-1778.
    • (2004) Lancet , vol.364 , pp. 1773-1778
    • Lux, A.L.1    Edwards, S.W.2    Hancock, E.3
  • 45
    • 77953741161 scopus 로고    scopus 로고
    • Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: A multi-centre randomised trial
    • Darke K., Edwards S.W., Hancock E., et al. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: A multi-centre randomised trial. Arch Dis Child 2010, 95:382-386.
    • (2010) Arch Dis Child , vol.95 , pp. 382-386
    • Darke, K.1    Edwards, S.W.2    Hancock, E.3
  • 46
    • 62849105099 scopus 로고    scopus 로고
    • Multicenter long-term follow-up of children with idiopathic West syndrome: ACTH versus vigabatrin
    • Cohen-Sadan S., Kramer U., Ben-Zeev B., et al. Multicenter long-term follow-up of children with idiopathic West syndrome: ACTH versus vigabatrin. Eur J Neurol 2009, 16:482-487.
    • (2009) Eur J Neurol , vol.16 , pp. 482-487
    • Cohen-Sadan, S.1    Kramer, U.2    Ben-Zeev, B.3
  • 48
    • 0029997934 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort
    • French J.A., Mosier M., Walker S., et al. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort. Neurology 1996, 46:54-61.
    • (1996) Neurology , vol.46 , pp. 54-61
    • French, J.A.1    Mosier, M.2    Walker, S.3
  • 49
    • 0032947717 scopus 로고    scopus 로고
    • Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures
    • Dean C., Mosier M., Penry K. Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia 1999, 40:74-82.
    • (1999) Epilepsia , vol.40 , pp. 74-82
    • Dean, C.1    Mosier, M.2    Penry, K.3
  • 50
    • 0344118227 scopus 로고    scopus 로고
    • Vigabatrin, a GABAergic antiepileptic drug, causes concentric visual field defects
    • Kalviainen R., Nousiainen I., Mäntyjärvi M., et al. Vigabatrin, a GABAergic antiepileptic drug, causes concentric visual field defects. Neurology 1999, 53:922-926.
    • (1999) Neurology , vol.53 , pp. 922-926
    • Kalviainen, R.1    Nousiainen, I.2    Mäntyjärvi, M.3
  • 51
    • 0032762648 scopus 로고    scopus 로고
    • Characteristics of a unique visual field defect attributed to vigabatrin
    • Wild J.M., Martinez C., Reinshagen G., et al. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999, 40:1784-1794.
    • (1999) Epilepsia , vol.40 , pp. 1784-1794
    • Wild, J.M.1    Martinez, C.2    Reinshagen, G.3
  • 52
    • 0032763649 scopus 로고    scopus 로고
    • Visual dysfunction in patients receiving vigabatrin: Clinical and electrophysiologic findings
    • Miller N.R., Johnson M.A., Paul S.R., et al. Visual dysfunction in patients receiving vigabatrin: Clinical and electrophysiologic findings. Neurology 1999, 53:2082-2087.
    • (1999) Neurology , vol.53 , pp. 2082-2087
    • Miller, N.R.1    Johnson, M.A.2    Paul, S.R.3
  • 53
    • 77749276685 scopus 로고    scopus 로고
    • Evaluating risks for vigabatrin treatment
    • Krauss G.L. Evaluating risks for vigabatrin treatment. Epilepsy Curr 2009, 9:125-129.
    • (2009) Epilepsy Curr , vol.9 , pp. 125-129
    • Krauss, G.L.1
  • 54
    • 58849147016 scopus 로고    scopus 로고
    • Cerebral MRI abnormalities associated with vigabatrin therapy
    • Pearl P.L., Vezina L.G., Saneto R.P., et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia 2009, 50:184-194.
    • (2009) Epilepsia , vol.50 , pp. 184-194
    • Pearl, P.L.1    Vezina, L.G.2    Saneto, R.P.3
  • 55
    • 62149125476 scopus 로고    scopus 로고
    • Transient brain magnetic resonance imaging hyperintensity in basal ganglia and brain stem of epileptic infants treated with vigabatrin
    • Milh M., Villeneuve N., Chapon F., et al. Transient brain magnetic resonance imaging hyperintensity in basal ganglia and brain stem of epileptic infants treated with vigabatrin. J Child Neurol 2009, 24:305-315.
    • (2009) J Child Neurol , vol.24 , pp. 305-315
    • Milh, M.1    Villeneuve, N.2    Chapon, F.3
  • 56
    • 58849112158 scopus 로고    scopus 로고
    • Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy
    • Wheless J.W., Carmant L., Bebin M., et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia 2009, 50:195-205.
    • (2009) Epilepsia , vol.50 , pp. 195-205
    • Wheless, J.W.1    Carmant, L.2    Bebin, M.3
  • 57
    • 59449092002 scopus 로고    scopus 로고
    • Refinement of the binding site and mode of action of the anticonvulsant retigabine on KCNQ K+ channels
    • Lange W., Geissendörfer J., Schenzer A., et al. Refinement of the binding site and mode of action of the anticonvulsant retigabine on KCNQ K+ channels. Mol Pharmacol 2009, 75:272-280.
    • (2009) Mol Pharmacol , vol.75 , pp. 272-280
    • Lange, W.1    Geissendörfer, J.2    Schenzer, A.3
  • 58
    • 0033862433 scopus 로고    scopus 로고
    • Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels
    • Wickenden A.D., Yu W., Zou A., et al. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 2000, 58:591-600.
    • (2000) Mol Pharmacol , vol.58 , pp. 591-600
    • Wickenden, A.D.1    Yu, W.2    Zou, A.3
  • 59
    • 77953317302 scopus 로고    scopus 로고
    • Retigabine: The newer potential antiepileptic drug
    • Czuczwar P., Wojtak A., Cioczek-Czuczwar A., et al. Retigabine: The newer potential antiepileptic drug. Pharmacol Rep 2010, 62:211-219.
    • (2010) Pharmacol Rep , vol.62 , pp. 211-219
    • Czuczwar, P.1    Wojtak, A.2    Cioczek-Czuczwar, A.3
  • 60
    • 34247252905 scopus 로고    scopus 로고
    • Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures
    • Porter R.J., Partiot A., Sachdeo R., et al. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007, 68:1197-1204.
    • (2007) Neurology , vol.68 , pp. 1197-1204
    • Porter, R.J.1    Partiot, A.2    Sachdeo, R.3
  • 61
    • 57849141134 scopus 로고    scopus 로고
    • Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (Eilat IX)
    • Bialer M., Johannessen S.I., Levy R.H., et al. Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (Eilat IX). Epilepsy Res 2009, 83:1-43.
    • (2009) Epilepsy Res , vol.83 , pp. 1-43
    • Bialer, M.1    Johannessen, S.I.2    Levy, R.H.3
  • 62
    • 70350144535 scopus 로고    scopus 로고
    • Deletions involving both KCNQ2 and CHRNA4 present with benign familial neonatal seizures
    • Kurahashi H., Wang J.W., Ishii A., et al. Deletions involving both KCNQ2 and CHRNA4 present with benign familial neonatal seizures. Neurology 2009, 73:1214-1217.
    • (2009) Neurology , vol.73 , pp. 1214-1217
    • Kurahashi, H.1    Wang, J.W.2    Ishii, A.3
  • 63
    • 84875833269 scopus 로고    scopus 로고
    • Benign familial neonatal seizures
    • University of Washington, Seattle, WA, B. Stephens, R.A. Pagan, C.R. Dolan (Eds.)
    • Bellini G., Miceli F., Soldovieri M.V. Benign familial neonatal seizures. GeneReviews 2010, University of Washington, Seattle, WA. B. Stephens, R.A. Pagan, C.R. Dolan (Eds.).
    • (2010) GeneReviews
    • Bellini, G.1    Miceli, F.2    Soldovieri, M.V.3
  • 64
    • 49549119738 scopus 로고    scopus 로고
    • Brivaracetam: A rational drug discovery success story
    • Rogawski M.A. Brivaracetam: A rational drug discovery success story. Br J Pharmacol 2008, 154:1555-1557.
    • (2008) Br J Pharmacol , vol.154 , pp. 1555-1557
    • Rogawski, M.A.1
  • 65
    • 32544452985 scopus 로고    scopus 로고
    • Synaptic vesicle protein 2 enhances release probability at quiescent synapses
    • Custer K.L., Austin N.S., Sullivan J.M., et al. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci 2006, 26:1303-1313.
    • (2006) J Neurosci , vol.26 , pp. 1303-1313
    • Custer, K.L.1    Austin, N.S.2    Sullivan, J.M.3
  • 66
    • 34548397130 scopus 로고    scopus 로고
    • Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model
    • Kasteleijn-Nolst Trenite D.G., Genton P., Parain D., et al. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology 2007, 69:1027-1034.
    • (2007) Neurology , vol.69 , pp. 1027-1034
    • Kasteleijn-Nolst Trenite, D.G.1    Genton, P.2    Parain, D.3
  • 67
    • 42549127137 scopus 로고    scopus 로고
    • Efficacy and tolerability of 5 20, 50 mg/day Brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial-onset seizures
    • Brivaracetam N01193 Study Group
    • French J.A., Von Rosenstiel P. Efficacy and tolerability of 5 20, 50 mg/day Brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial-onset seizures. Epilepsia 2007, 48:400. Brivaracetam N01193 Study Group.
    • (2007) Epilepsia , vol.48 , pp. 400
    • French, J.A.1    Von Rosenstiel, P.2
  • 68
    • 42549143839 scopus 로고    scopus 로고
    • Efficacy and tolerability of 50 and 150 mg/day Brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial-onset epilepsy
    • b.o.t.B.N.S.G.
    • van Paesschen W. Efficacy and tolerability of 50 and 150 mg/day Brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial-onset epilepsy. Epilepsia 2007, 48:329. b.o.t.B.N.S.G.,.
    • (2007) Epilepsia , vol.48 , pp. 329
    • van Paesschen, W.1
  • 69
    • 78650298362 scopus 로고    scopus 로고
    • Accessed November 1, 2010
    • Accessed November 1, 2010. http://professionals.epilepsy.com/page/announce_42909.html.
  • 70
    • 42549172614 scopus 로고    scopus 로고
    • Safety and tolerability of Brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial-onset seizures
    • Brodsky A., von Rosenstiel P. Safety and tolerability of Brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial-onset seizures. Epilepsia 2008, 48:342.
    • (2008) Epilepsia , vol.48 , pp. 342
    • Brodsky, A.1    von Rosenstiel, P.2
  • 71
    • 78650280401 scopus 로고    scopus 로고
    • Accessed November 10, 2010
    • Accessed November 10, 2010. http://www.lundbeck.com/investor/releases/ReleaseDetails/Release_1418334_EN.asp.
  • 72
    • 0034108997 scopus 로고    scopus 로고
    • Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype
    • McKernan R.M., Rosahl T.W., Reynolds D.S., et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 2000, 3:587-592.
    • (2000) Nat Neurosci , vol.3 , pp. 587-592
    • McKernan, R.M.1    Rosahl, T.W.2    Reynolds, D.S.3
  • 74
    • 44949114187 scopus 로고    scopus 로고
    • Clobazam as an add-on in the management of refractory epilepsy
    • CD004154
    • Michael B. Clobazam as an add-on in the management of refractory epilepsy. Cochrane Database Syst Rev 2008, 16. CD004154.
    • (2008) Cochrane Database Syst Rev , vol.16
    • Michael, B.1
  • 75
    • 17144474677 scopus 로고    scopus 로고
    • Clobazam has equivalent efficacy to carbamazepinephenytoin as monotherapy for childhood epilepsy: Canadian Study Group for Childhood Epilepsy
    • Clobazam has equivalent efficacy to carbamazepinephenytoin as monotherapy for childhood epilepsy: Canadian Study Group for Childhood Epilepsy. Epilepsia 1998, 39:952-959.
    • (1998) Epilepsia , vol.39 , pp. 952-959
  • 76
    • 0023206004 scopus 로고
    • Clobazam in therapy-resistant patients with partial epilepsy: A double-blind placebo-controlled crossover study
    • Koeppen D., Baruzzi A., Capozza M., et al. Clobazam in therapy-resistant patients with partial epilepsy: A double-blind placebo-controlled crossover study. Epilepsia 1987, 28:495-506.
    • (1987) Epilepsia , vol.28 , pp. 495-506
    • Koeppen, D.1    Baruzzi, A.2    Capozza, M.3
  • 77
    • 0025124844 scopus 로고
    • Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood
    • Keene D.L., Whiting S., Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can J Neurol Sci 1990, 17:317-319.
    • (1990) Can J Neurol Sci , vol.17 , pp. 317-319
    • Keene, D.L.1    Whiting, S.2    Humphreys, P.3
  • 78
    • 77953217352 scopus 로고    scopus 로고
    • Epileptogenesis provoked by prolonged experimental febrile seizures: Mechanisms and biomarkers
    • Dube C.M., Ravizza T., Hamamura M., et al. Epileptogenesis provoked by prolonged experimental febrile seizures: Mechanisms and biomarkers. J Neurosci 2010, 30:7484-7494.
    • (2010) J Neurosci , vol.30 , pp. 7484-7494
    • Dube, C.M.1    Ravizza, T.2    Hamamura, M.3
  • 79
    • 39749159858 scopus 로고    scopus 로고
    • Early treatment suppresses the development of spike-wave epilepsy in a rat model
    • Blumenfeld H., Klein J.P., Schridde U., et al. Early treatment suppresses the development of spike-wave epilepsy in a rat model. Epilepsia 2008, 49:400-409.
    • (2008) Epilepsia , vol.49 , pp. 400-409
    • Blumenfeld, H.1    Klein, J.P.2    Schridde, U.3
  • 80
    • 71649091226 scopus 로고    scopus 로고
    • Favourable prognostic factors with infantile spasms
    • Riikonen R.S. Favourable prognostic factors with infantile spasms. Eur J Paediatr Neurol 2010, 14:13-18.
    • (2010) Eur J Paediatr Neurol , vol.14 , pp. 13-18
    • Riikonen, R.S.1
  • 81
    • 22544488406 scopus 로고    scopus 로고
    • Infantile spasms and intellectual outcomes in children with tuberous sclerosis complex
    • Goh S., Kwiatkowski D.J., Dorer D.J., et al. Infantile spasms and intellectual outcomes in children with tuberous sclerosis complex. Neurology 2005, 65:235-238.
    • (2005) Neurology , vol.65 , pp. 235-238
    • Goh, S.1    Kwiatkowski, D.J.2    Dorer, D.J.3
  • 82
    • 78649289488 scopus 로고    scopus 로고
    • Long-term outcome of 32 children with encephalopathy with status epilepticus during sleep, or ESES syndrome
    • Liukkonen E., Kantola-Sorsa E., Paetau R., et al. Long-term outcome of 32 children with encephalopathy with status epilepticus during sleep, or ESES syndrome. Epilepsia 2010, 51:2023-2032.
    • (2010) Epilepsia , vol.51 , pp. 2023-2032
    • Liukkonen, E.1    Kantola-Sorsa, E.2    Paetau, R.3
  • 83
    • 70350619353 scopus 로고    scopus 로고
    • The dilemma on treatment of the EEG: A justified perspective
    • Jaseja H. The dilemma on treatment of the EEG: A justified perspective. Epilepsy Behav 2009, 16:561-562.
    • (2009) Epilepsy Behav , vol.16 , pp. 561-562
    • Jaseja, H.1
  • 84
    • 77954529084 scopus 로고    scopus 로고
    • The natural history of epilepsy in tuberous sclerosis complex
    • Chu-Shore C.J., Major P., Camposano S., et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010, 51:1236-1241.
    • (2010) Epilepsia , vol.51 , pp. 1236-1241
    • Chu-Shore, C.J.1    Major, P.2    Camposano, S.3
  • 85
    • 69449091966 scopus 로고    scopus 로고
    • Neuropsychological status at seizure onset in children: Risk factors for early cognitive deficits
    • Fastenau P.S., Johnson C.S., Perkins S.M., et al. Neuropsychological status at seizure onset in children: Risk factors for early cognitive deficits. Neurology 2009, 73:526-534.
    • (2009) Neurology , vol.73 , pp. 526-534
    • Fastenau, P.S.1    Johnson, C.S.2    Perkins, S.M.3
  • 86
    • 37249081697 scopus 로고    scopus 로고
    • Antiepileptic drug development in children: Considerations for a revisited strategy
    • Chiron C., Dulac O., Pons G. Antiepileptic drug development in children: Considerations for a revisited strategy. Drugs 2008, 68:17-25.
    • (2008) Drugs , vol.68 , pp. 17-25
    • Chiron, C.1    Dulac, O.2    Pons, G.3
  • 88
    • 77649319457 scopus 로고    scopus 로고
    • Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy
    • Glauser T.A., Cnaan A., Shinnar S., et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010, 362:790-799.
    • (2010) N Engl J Med , vol.362 , pp. 790-799
    • Glauser, T.A.1    Cnaan, A.2    Shinnar, S.3
  • 89
    • 0033544351 scopus 로고    scopus 로고
    • A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children: Lamictal Pediatric Partial Seizure Study Group
    • Duchowny M., Pellock J.M., Graf W.D., et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children: Lamictal Pediatric Partial Seizure Study Group. Neurology 1999, 53:1724-1731.
    • (1999) Neurology , vol.53 , pp. 1724-1731
    • Duchowny, M.1    Pellock, J.M.2    Graf, W.D.3
  • 90
    • 0032800766 scopus 로고    scopus 로고
    • Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study: Gabapentin Paediatric Study Group
    • Appleton R., Fichtner K., LaMoreaux L., et al. Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study: Gabapentin Paediatric Study Group. Epilepsia 1999, 40:1147-1154.
    • (1999) Epilepsia , vol.40 , pp. 1147-1154
    • Appleton, R.1    Fichtner, K.2    LaMoreaux, L.3
  • 91
    • 0033594350 scopus 로고    scopus 로고
    • A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children: Topiramate YP Study Group
    • Elterman R.A., Glauser T.A., Wyllie E., et al. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children: Topiramate YP Study Group. Neurology 1999, 52:1338-1344.
    • (1999) Neurology , vol.52 , pp. 1338-1344
    • Elterman, R.A.1    Glauser, T.A.2    Wyllie, E.3
  • 92
    • 18844471793 scopus 로고    scopus 로고
    • Adjunctive therapy with oxcarbazepine in children with partial seizures: The Oxcarbazepine Pediatric Study Group
    • Glauser T.A., Nigro M., Sachdeo R., et al. Adjunctive therapy with oxcarbazepine in children with partial seizures: The Oxcarbazepine Pediatric Study Group. Neurology 2000, 54:2237-2244.
    • (2000) Neurology , vol.54 , pp. 2237-2244
    • Glauser, T.A.1    Nigro, M.2    Sachdeo, R.3
  • 93
    • 33745665605 scopus 로고    scopus 로고
    • Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures
    • Glauser T.A., Ayala R., Elterman R.D., et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006, 66:1654-1660.
    • (2006) Neurology , vol.66 , pp. 1654-1660
    • Glauser, T.A.1    Ayala, R.2    Elterman, R.D.3
  • 94
    • 0032976081 scopus 로고    scopus 로고
    • A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome: Topiramate YL Study Group
    • Sachdeo R.C., Glauser T.A., Ritter F., et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome: Topiramate YL Study Group. Neurology 1999, 52:1882-1887.
    • (1999) Neurology , vol.52 , pp. 1882-1887
    • Sachdeo, R.C.1    Glauser, T.A.2    Ritter, F.3
  • 95
    • 0034638786 scopus 로고    scopus 로고
    • Stiripentol in severe myoclonic epilepsy in infancy: A randomised placebo-controlled syndrome-dedicated trial. STICLO study group
    • Chiron C., Marchand M.C., Tran A., et al. Stiripentol in severe myoclonic epilepsy in infancy: A randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000, 356:1638-1642.
    • (2000) Lancet , vol.356 , pp. 1638-1642
    • Chiron, C.1    Marchand, M.C.2    Tran, A.3
  • 96
    • 0031453973 scopus 로고    scopus 로고
    • Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome in Lamictal Lennox-Gastaut Study Group
    • Motte J., Trevathan E., Arvidsson J.F., et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome in Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997, 337:1807-1812.
    • (1997) N Engl J Med , vol.337 , pp. 1807-1812
    • Motte, J.1    Trevathan, E.2    Arvidsson, J.F.3
  • 97
    • 0027287361 scopus 로고
    • A controlled trial of diazepam administered during febrile illnesses to prevent recurrence of febrile seizures
    • Rosman N.P., Colton T., Labazzo J., et al. A controlled trial of diazepam administered during febrile illnesses to prevent recurrence of febrile seizures. N Engl J Med 1993, 329:79-84.
    • (1993) N Engl J Med , vol.329 , pp. 79-84
    • Rosman, N.P.1    Colton, T.2    Labazzo, J.3
  • 98
    • 38549178440 scopus 로고    scopus 로고
    • Treatment of pediatric epilepsy: European expert opinion, 2007
    • Wheless J.W., Clarke D.F., Arzimanoglou A., et al. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007, 9:353-412.
    • (2007) Epileptic Disord , vol.9 , pp. 353-412
    • Wheless, J.W.1    Clarke, D.F.2    Arzimanoglou, A.3
  • 99
    • 33750366552 scopus 로고    scopus 로고
    • Pharmacokinetic variability of newer antiepileptic drugs: When is monitoring needed?
    • Johannessen S.I., Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: When is monitoring needed?. Clin Pharmacokinet 2006, 45:1061-1075.
    • (2006) Clin Pharmacokinet , vol.45 , pp. 1061-1075
    • Johannessen, S.I.1    Tomson, T.2
  • 100
    • 33645529117 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age
    • Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet 2006, 45:351-363.
    • (2006) Clin Pharmacokinet , vol.45 , pp. 351-363
    • Perucca, E.1
  • 101
    • 45749116975 scopus 로고    scopus 로고
    • Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy
    • Perucca E., Cloyd J., Critchley D., et al. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008, 49:1123-1141.
    • (2008) Epilepsia , vol.49 , pp. 1123-1141
    • Perucca, E.1    Cloyd, J.2    Critchley, D.3
  • 102
    • 0018832032 scopus 로고
    • Pharmacokinetic aspects of anxiolytic drug therapy
    • Greenblatt D.J., Shader R.I. Pharmacokinetic aspects of anxiolytic drug therapy. Can J Neurol Sci 1980, 7:269-270.
    • (1980) Can J Neurol Sci , vol.7 , pp. 269-270
    • Greenblatt, D.J.1    Shader, R.I.2
  • 103
    • 55949109998 scopus 로고    scopus 로고
    • Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics
    • Riss J., Cloyd J., Gates J., et al. Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics. Acta Neurol Scand 2008, 118:69-86.
    • (2008) Acta Neurol Scand , vol.118 , pp. 69-86
    • Riss, J.1    Cloyd, J.2    Gates, J.3
  • 104
    • 0026674193 scopus 로고
    • Vigabatrin. Clinical pharmacokinetics
    • Rey E., Pons G., Olive G. Vigabatrin. Clinical pharmacokinetics. Clin Pharmacokinet 1992, 23:267-278.
    • (1992) Clin Pharmacokinet , vol.23 , pp. 267-278
    • Rey, E.1    Pons, G.2    Olive, G.3
  • 105
    • 0019797875 scopus 로고
    • Clobazam plasma concentrations: pharmacokinetic study in healthy volunteers and data in epileptic patients
    • Tedeschi G., Riva R., Baruzzi A. Clobazam plasma concentrations: pharmacokinetic study in healthy volunteers and data in epileptic patients. Br J Clin Pharmacol 1981, 11:619-622.
    • (1981) Br J Clin Pharmacol , vol.11 , pp. 619-622
    • Tedeschi, G.1    Riva, R.2    Baruzzi, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.